Loss of heterozygosity (LOH) for loci on chromosome 10 and 17p and amplification of the epidermal growth factor receptor (EGFR) gene on chromosome 7 are the most frequent genetic alterations in human malignant astrocytoma. LOH 10 is predominantlI associated with high-grade astrocvtomas and has been reported to occur in 60-75% of cases (James et al.. 1988 : Fujimoto et al.. 1989 : Fults et al.. 1990 : Watanabe et al.. 1990 : Venter & Thomas. 1991 : Fults et al.. 1992 . LOH 17p is apparent in 30-35% of astrocytomas of all malignancy grades (El-Azouzi et al.. 1989; Fults et al.. 1989 : James et al.. 1989 . It is frequently found in association with mutation of the TP53 gene on 17p (Nigro et al.. 1989 : Chung et al.. 1991 : Frankel et al.. 1992 : Fults et al.. 1992 : Von Deimling et al.. 1992a . EGFR gene amplification has been noted in about 40% of high-grade astrocytomas (Wong et al.. 1987 : Bigner et al.. 1988 : Ekstrand et al.. 1991 . Less frequent genetic alterations in high-grade astrocytoma include LOH for loci on chromosomes 13q and 22q. which are also found in low-grade tumours. and LOH for loci on chromosomes 9p. lp and 19q (Collins & James. 1993). Finally. amplification of several proto-oncogenes. including MYCN. GLI and MDMV2. and the anonymous marker D17S67 has been noted in a low percentage of high-grade astrocytomas (Collins & James. 1993 : Bijlsma et al.. 1994 (grades III and IV) were used for RFLP (restriction fragment length polymorphism) analysis. except for tumour samples 316. 449 and 673. These samples represent high-grade parts of heterogeneous high-grade tumours that were previously molecularly analysed (Leenstra et al., 1992) . The molecular data for tumours 1197. 1672 and 1683 have been published before (Bijlsma et al.. 1994 Kernohan and Sayre (1952 
Results

Genetic alterations
The study included 47 high-grade tumours. These were, according to Kernohan and Sayre (1952) . ten grade III and 37 grade IV astrocytomas. For the purpose of this investigation thev wvere considered as one group because. in the Kernohan system. patients with grade III and grade IV tumours do not differ in median post-operative survival (Scanlon & Taylor. 1979 Figure 2 . Figure 2a shows hybridisation of the TP53 cDNA probe pProSP53 to BglII-digested tumour and coresponding leucocyte DNA. The 12 and 9kb allelic fragments remain in the tumour. Figure 2b shows Amplification levels ranged from eight to 33 times (Table I) . Although EGFR gene amplification is usually found in a higher proportion of high-grade astrocytomas. a similar low percentage has been reported in another study (Venter & Thomas. 1991 51  27  25  51  37  39  41  53  65  59  42  66  52  69  44  52  59  74  57  73  60  71  71  60  65  64  59  69  66  44  46  63  64  45  49  62  65  28  31  48  73  51  63  42  63  37  52   Grade  III  III  III  III  IV  IV  IV  III  III  III  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  IV  III  IV  IV  IV  IV  IV  IV  IV  III  III  IV  IV  IV  IV  IV  IV  IV  IV (3) - (4) -(4)' - (7) (2) - (3) + (4) + ( 
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(5) Genetic data (number of informative markers between brackets): 'Normaised amplification levels of 12, 11,26,8,33, 11, 15, 15in tumours 449, 858, 890,891,893, 1194, 1666, 1683 respectively. bDeletion of part of chromosome arm 17p, including the TP53 gene region. 'Deletion ofD1OS25 in non-critical region (Figure 1) . dDeletion of part ofchromosome 10 (Figure 1 ). 'Deletion of part ofchromosome arm 17p, not including the TP53 gene region (Figure 2 ).
II. The Student-Newman-Keuls multiple range test revealed a difference between the group of patients showing only LOH 17p and the other three groups. The mean age of these three groups did not differ significantly.
Genetic alterations in relation to post-operative survival Kaplan -Meier survival curves were constructed for the four groups of patients (Figure 3) . The median survivals are given in Table II . The survival curves were compared by log-rank test. The resulting P-values were adjusted for multiple comparisons by the procedure of Hommel (see Wright, 1992 Figure 3) . Type 1 patients differ from the type 2. 3 and 4 patients in mean age at operation. and age is an important variable with regard to survival (Burger & Green. 1987 : Salford et al.. 1988 Comparable studies with regard to survival in patients with high-grade astrocytomas and with the same set of genetic alterations have, to our knowledge. not been published. Bigner et al. (1988) studied EGFR gene amplification in malignant gliomas but could not detect a significant effect on median survival. In contrast to this, Hurtt et al. (1992) reported a significant and age-independent decrease in median survival in patients with EGFR gene amplification. If we consider EGFR gene amplification as an independent variant in Cox's regression model. then it has age-corrected prognostic significance (P = 0.004). However, as noted by Von Deimling et al. (1992b) and as shown in Table I . EGFR gene amplification is strongly associated with LOH 10. Our type 4 patients with LOH 10 + EGFR gene amplification had a similar mean age to the type 2 patients with LOH 10 onlv (59 and 54 years respectively). The difference in survival between both groups of patients is not significant (P = 0.17). thereby questioning the prognostic importance of EGFR gene amplification. Thus, the contradictory reports on the prognostic importance of EGFR gene amplification could be caused by differences in the chromosome 10 status of the tumours that were examined. In all our type 1 patients. the tumour occupied a frontal position. As noted before, these patients were relatively young at presentation and had a favourable prognosis. This observation genetically supports other clinical studies reporting a longer sur'Vival time for patients with frontally located lesions (North et al.. 1990; Curran et al., 1992; Ayoubi et al.. 1993 ).
In summary. our data suggest that histopathologicallv high-grade astrocytomas constitute a genetically heterogeneous group of tumours. They can be subdivided by using allele loss on chromosomes 10 and 17p and EGFR gene amplification as genetic parameters. The genetic subdiv%ision into four types correlates with mean age and median survival of the different groups of patients. Under certain assumptions, the genetic subdivision has major prognostic significance. The discrepancies between the results presented here and those of others may in part be explained bv the small sample sizes in the studies.
